Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

data

30 posts
NNovartis
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Read More

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

  • 2026-08-19
Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goals New AZALEA-TIMI…
BBasel
Basel Ziyadeh, Julphar Chief Executive Officer, Lula Mohanty, Managing Partner, IBM Consulting, and Sergio Maccotta, Senior Vice President and General Manager SAP MEA South, SAP. Image Courtesy: Julphar
Read More

Julphar Taps IBM & SAP for Enterprise Transformation

  • 2026-07-22
Gulf Pharmaceutical Industries (Julphar), in collaboration with IBM and SAP, recently announced a strategic initiative to transform its…
SSwitzerland
UK agrees FTA with Switzerland: What’s in it for tech? | techUK
Read More

UK agrees FTA with Switzerland: What’s in it for tech? | techUK

  • 2026-07-16
On 13/07/2026, DBT announced that the UK has agreed an FTA with Switzerland. The Deal has been hailed…
SSwitzerland
UK agrees FTA with Switzerland: What’s in it for tech? | techUK
Read More

UK agrees FTA with Switzerland: What’s in it for tech? | techUK

  • 2026-07-16
On 13/07/2026, DBT announced that the UK has agreed an FTA with Switzerland. The Deal has been hailed…
RRoche
Featured Image for Innovaccer Inc.
Read More

Innovaccer Announces Collaboration with Roche to Develop

  • 2026-06-24
SAN FRANCISCO, Sept. 29, 2021 (GLOBE NEWSWIRE) — Today Innovaccer Inc., the Health Cloud company, announced it has…
AABB
PSYONIC Arms NVIDIA And ABB With Robots Dexterity Data
Read More

PSYONIC Arms NVIDIA And ABB With Robots Dexterity Data

  • 2026-06-22
Nvidia, PSYONIC, and ABB are collaborating for Human Dexterity Data PSYONIC Physical AI, like robots and humanoids, has…
NNovartis
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Read More

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

  • 2026-06-12
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable…
NNovartis
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Read More

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

  • 2026-06-08
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be…
NNovartis
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Read More

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

  • 2026-06-03
Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent…
NNovartis
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Read More

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

  • 2026-05-28
Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented124-week Phase I/II zigakibart…
NNovartis
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Read More

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

  • 2026-05-21
Pluvicto®PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali®…
RRoche
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Read More

Roche to present new data at ASCO 2026, reinforcing giredestrant’s potential to transform the treatment paradigm in early breast cancer

  • 2026-05-19
New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant…
Switzerland
www.europesays.com